ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
GlobalData on MSN

BCG and Hippocratic AI to deploy generative agents across life sciences

The collaboration seeks to address this gap by transitioning organisations from limited experimentation to enterprise-wide ...

The BCG Compression Tee is My Ultimate Must-Have Piece of Running Gear—And Costs Under $20

The BCG compression tee sees me through every type of workout: 400-meter repeats, tempo runs, hill sprints, as well as ...

ImmunityBio extends gains after FDA views on Anktiva label expansion

ImmunityBio (IBRX) stock jumps after the FDA meeting on the company's plans to seek label expansion for bladder cancer therapy Anktiva. Read more here.
Forbes

BCG Against Coronavirus: Less Hype And More Evidence, Please

I was born and raised in India. On the day I was born, I am told I got my first jab, a vaccine called BCG (bacille Calmette-Guerin). Kids born in India today still get this vaccine. This century-old ...
PharmiWeb

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development ...